Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2013	Aug. 01, 2013
Document Information [Line Items]
Entity Registrant Name	Bacterin International Holdings, Inc.
Entity Central Index Key	0001453593
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		51,366,979
Trading Symbol	BONE
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2013
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2013

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2013	Dec. 31, 2012
ASSETS
Cash and cash equivalents	$ 5,135,974	$ 4,926,066
Trade accounts receivable, net of allowance for doubtful accounts of $518,419 and $1,576,955, respectively	6,226,619	7,154,065
Inventories, net	13,803,063	13,141,421
Prepaid and other current assets	667,871	353,271
Total current assets	25,833,527	25,574,823
Non-current inventories	1,238,225	1,238,225
Property and equipment, net	5,458,272	5,234,867
Intangible assets, net	564,693	592,378
Goodwill	728,618	728,618
Other assets	1,295,718	1,126,643
Total Assets	35,119,053	34,495,554
LIABILITIES & STOCKHOLDERS' EQUITY
Accounts payable	4,245,745	3,997,789
Accounts payable - related party	478,762	418,922
Accrued liabilities	2,391,313	2,400,090
Warrant derivative liability	1,374,044	984,356
Current portion of capital lease obligations	160,267	149,729
Current portion of royalty liability	804,250	698,408
Current portion of long-term debt	46,320	45,135
Total current liabilities	9,500,701	8,694,429
Long-term Liabilities:
Capital lease obligation, less current portion	162,880	245,703
Long term royalty liability, less current portion	6,677,474	6,839,935
Long-term debt, less current portion	15,342,246	14,483,102
Total Liabilities	31,683,301	30,263,169
Commitments and Contingencies
Stockholders' Equity
Preferred stock, $.000001 par value; 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $.000001 par value; 95,000,000 shares authorized; 51,528,544 shares issued and outstanding as of June 30, 2013 and 42,877,770 shares issued and outstanding as of December 31, 2012	52	43
Additional paid-in capital	55,253,597	51,897,890
Accumulated deficit	(51,817,897)	(47,665,548)
Total Stockholders’ Equity	3,435,752	4,232,385
Total Liabilities & Stockholders’ Equity	$ 35,119,053	$ 34,495,554

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Jun. 30, 2013	Dec. 31, 2012
Trade accounts receivable, allowance for doubtful accounts (in dollars)	$ 518,419	$ 1,576,955
Preferred stock, par value (in dollars per share)	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.000001	$ 0.000001
Common stock, shares authorized	95,000,000	95,000,000
Common stock, shares issued	51,528,544	42,877,770
Common Stock, shares outstanding	51,528,544	42,877,770

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Revenue
Tissue sales	$ 8,196,554	$ 8,113,605	$ 16,719,902	$ 15,784,554
Royalties and other	70,294	94,667	165,753	193,719
Total Revenue	8,266,848	8,208,272	16,885,655	15,978,273
Cost of tissue and medical devices sales	3,572,674	2,329,432	6,693,360	4,188,154
Gross Profit	4,694,174	5,878,840	10,192,295	11,790,119
Operating Expenses
General and administrative	2,256,287	2,319,851	5,113,369	4,910,623
Sales and marketing	4,205,333	3,835,209	8,003,710	7,981,552
Depreciation and amortization	100,470	95,206	206,848	214,280
Non-cash consulting expense	(932)	(24,069)	(31,229)	304,184
Total Operating Expenses	6,561,158	6,226,197	13,292,698	13,410,639
Loss from Operations	(1,866,984)	(347,357)	(3,100,403)	(1,620,520)
Other Income (Expense)
Interest expense	(1,174,648)	(266,200)	(2,238,636)	(409,052)
Change in warrant derivative liability	460,270	1,301,576	1,095,625	1,519,127
Other income	98,271	42,498	91,065	194,167
Total Other Income (Expense)	(616,107)	1,077,874	(1,051,946)	1,304,242
Net Loss Before (Provision) Benefit for Income Taxes	(2,483,091)	730,517	(4,152,349)	(316,278)
(Provision) Benefit for Income Taxes
Current	0	0	0	0
Deferred	0	0	0	0
Net (Loss) Income	$ (2,483,091)	$ 730,517	$ (4,152,349)	$ (316,278)
Net (loss) income per share:
Basic (in dollars per share)	$ (0.05)	$ 0.02	$ (0.09)	$ (0.01)
Dilutive (in dollars per share)	$ (0.05)	$ 0.02	$ (0.09)	$ (0.01)
Shares used in the computation:
Basic (in shares)	45,250,699	42,695,350	44,095,052	42,121,718
Dilutive (in shares)	45,250,699	44,683,663	44,095,052	42,121,718

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	Jun. 30, 2013	Jun. 30, 2012
Operating activities:
Net loss	$ (4,152,349)	$ (316,278)
Noncash adjustments:
Depreciation and amortization	394,849	403,252
Amortization of debt discount	583,181	53,707
Non-cash consulting expense/stock option expense	236,880	1,038,780
Provision for losses on accounts receivable and inventory	258,367	(23,733)
(Gain) loss on disposal of assets	(500)	7,902
Change in derivative warrant liability	(1,095,625)	(1,519,127)
Reduction of contingent liability	(91,740)	(358,426)
Changes in operating assets and liabilities:
Accounts receivable	156,335	524,232
Inventories	(148,898)	(3,944,422)
Prepaid and other assets	(183,675)	(740,338)
Accounts payable	307,796	1,006,175
Accrued liabilities	180,491	(993,897)
Net cash used in operating activities	(3,554,888)	(4,862,173)
Investing activities:
Purchases of property and equipment	(579,920)	(870,569)
Intangible asset additions	(10,149)	0
Net cash used in investing activities	(590,069)	(870,569)
Financing activities:
Proceeds from the issuance of long-term debt	0	2,741,720
Payments on long-term debt	(22,852)	(445,534)
Payments on capital leases	(72,285)	(21,085)
Net proceeds from issuance of stock	4,450,002	3,899,996
Proceeds from exercise of options	0	20,099
Net cash provided by financing activities	4,354,865	6,195,196
Net change in cash and cash equivalents	209,908	462,454
Cash and cash equivalents at beginning of period	4,926,066	751,111
Cash and cash equivalents at end of period	$ 5,135,974	$ 1,213,565

Business Description and Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

(1) Business Description and Summary of Significant Accounting Policies

Business Description

The accompanying consolidated financial statements include the accounts of Bacterin International Holdings, Inc., a Delaware corporation, and its wholly owned subsidiary, Bacterin International, Inc., a Nevada corporation, (collectively, the “Company” or “Bacterin”). All intercompany balances and transactions have been eliminated in consolidation. Bacterin’s biologics division develops, manufactures and markets biologics products to domestic and international markets. Bacterin’s proprietary methods are used in human allografts to create stem cell scaffolds and promote bone and other tissue growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of skull healing following neurosurgery and regeneration in knee and other joint surgeries.

Bacterin’s device division develops and licenses coatings for various medical device applications.

An operating segment is a component of an enterprise whose operating results are regularly reviewed by the enterprise’s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance. The primary performance measure used by management is net income or loss. The Company operates in two distinct lines of business consisting of the biologics and devices divisions. However, due to the immaterial revenue from devices to date, the Company reports as one segment.

The Company's revenue is derived principally from the sale or license of its medical products, coatings and device implants. The markets in which the Company competes are highly competitive and rapidly changing. Significant technological advances, changes in customer requirements, or the emergence of competitive products with new capabilities or technologies could adversely affect the Company's operating results. The Company's business could be harmed by a decline in demand for, or in the prices of, its products or as a result of, among other factors, any change in pricing or distribution model, increased price competition, changes in government regulations or a failure by the Company to keep up with technological change. Further, a decline in available tissue donors could have an adverse impact on our business.

The accompanying interim condensed consolidated financial statements of Bacterin for the three and six months ended June 30, 2013 and 2012 are unaudited and are prepared in accordance with accounting principles generally accepted in the United States of America. They do not include all disclosures required by generally accepted accounting principles for annual financial statements, but in the opinion of management, include all adjustments, consisting only of normal recurring items, necessary for a fair presentation. Interim results are not necessarily indicative of results which may be achieved in the future for the full year ending December 31, 2013.

These financial statements should be read in conjunction with the financial statements and notes thereto which are included in Bacterin’s Annual Report on Form 10-K for the year ended December 31, 2012. The accounting policies set forth in those annual financial statements are the same as the accounting policies utilized in the preparation of these financial statements, except as modified for appropriate interim financial statement presentation.

Concentrations and Credit Risk

The Company’s accounts receivable are due from a variety of health care organizations and distributors throughout the world. Approximately 98% and 97% of sales were in the United States for the six months ended June 30, 2013 and 2012, respectively. One customer accounted for approximately 8% and 7% of the Company’s revenue for the six months ended June 30, 2013 and 2012, respectively. One customer represented 15% and 21% of accounts receivable at June 30, 2013 and 2012, respectively. The Company provides for uncollectible amounts when specific credit issues arise. Management’s estimates for uncollectible amounts have been adequate during prior periods, and management believes that all significant credit risks have been identified at June 30, 2013.

Revenue by geographical region is as follows:

	Six months ended June 30,
	2013		2012
United States	$	16,562,064	$	15,507,794
Rest of World		323,591		470,479
	$	16,885,655	$	15,978,273

Use of Estimates

The preparation of the financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period; the carrying amount of property and equipment and intangible assets; valuation allowances for trade receivables and deferred income tax assets; valuation of the warrant derivative liability; inventory reserve; contingent consideration from acquisitions; royalty liability; and estimates for the fair value of stock options grants and other equity awards upon which the Company determines stock-based compensation expense. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an original maturity date of three months or less to be cash equivalents. Cash equivalents are recorded at cost, which approximates market value. At times the Company maintains deposits in financial institutions in excess of federally insured limits.

Accounts Receivable

Accounts receivable represents amounts due from customers for which revenue has been recognized. Normal terms on trade accounts receivable are net 30 days and some customers are offered discounts for early pay. The Company performs credit evaluations when considered necessary, but generally does not require collateral to extend credit.

The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing receivables. The Company determines the allowance based on factors such as historical collection experience, customer's current creditworthiness, customer concentration, age of accounts receivable balance, general economic conditions that may affect a customer's ability to pay and management judgment. Actual customer collections could differ from estimates. Account balances are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Provisions to the allowance for doubtful accounts are charged to expense. The Company does not have any off-balance sheet credit exposure related to its customers.

Accounts Payable - Related Party

Accounts payable to a related party includes amounts due to American Donor Services, a supplier of donors to the Company. See Note 14, “Related Party Transactions” below.

Inventories

Inventories are stated at the lower of cost or market. Cost is determined using the specific identification method and includes materials, labor and overhead. The Company calculates an inventory reserve for estimated obsolescence or excess inventory based on historical usage and sales, as well as assumptions about future demand for its products. These estimates for excess and obsolete inventory are reviewed and updated on a quarterly basis. Increases in the inventory reserves result in a corresponding expense, which is generally recorded to cost of tissue and medical devices sales. Inventories where the sales cycle is estimated to be beyond twelve months are classified as Non-current inventories.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to seven years for computers and equipment, and 30 years for buildings. Leasehold improvements are depreciated over the shorter of their estimated useful life or the remaining term of the lease. Repairs and maintenance are expensed as incurred.

Goodwill

Goodwill represents the excess of costs over fair value of assets of businesses acquired. Goodwill and intangible assets acquired in a purchase business combination and determined to have indefinite useful lives are not amortized, instead are tested for impairment at least annually and whenever events or circumstances indicate the carrying amount of the asset may not be recoverable. In its evaluation of goodwill, the Company performs an assessment of qualitative factors to determine if it is more-likely-than-not that goodwill might be impaired and whether it is necessary to perform the two-step goodwill impairment. The Company conducts its annual impairment test on December 31 of each year. See Note 3, “Goodwill” below.

Derivative Instruments

The Company accounts for its derivative instruments in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 815 “Accounting for Derivative Instruments and Hedging Activities”. The only derivative instruments presented in the accompanying consolidated financial statements relates to warrants issued in connection with certain debt financings. The Company has not designated its warrant derivative liability as a hedging instrument as described in ASC 815 and any changes in the fair market value of the warrant derivative liability is recognized in the consolidated statement of operations during the period of change. See Note 10, “Warrants” below.

Intangible Assets

Intangible assets with estimable useful lives must be amortized over their respective estimated useful lives to their estimated residual values, and reviewed for impairment whenever events or circumstances indicate their carrying amount may not be recoverable. Intangible assets include trademarks, customer lists and patents and include costs to acquire and protect Company patents. Intangible assets are carried at cost less accumulated amortization. The Company amortizes these assets on a straight-line basis over their estimated useful lives of five years for customer lists and 15 years for all other intangible assets.

Revenue Recognition

Revenue is recognized when all of the following criteria are met: a) the Company has entered into a legally binding agreement with the customer; b) the products or services have been delivered; c) the Company's fee for providing the products and services is fixed or determinable; and d) collection of the Company’s fee is probable.

The Company’s policy is to record revenue net of any applicable sales, use, or excise taxes. If an arrangement includes a right of acceptance or a right to cancel, revenue is recognized when acceptance is received or the right to cancel has expired.

The Company ships to certain customers under consignment arrangements whereby the Company’s product is stored by the customer. The customer is required to report the use to the Company and upon such notice, the Company invoices the customer and revenue is recognized when above criteria has been met.

The Company also receives royalty revenue from third parties related to licensing agreements. The Company has royalty agreements with Nufix, RyMed and Bard Access Systems. Revenue under these agreements represented less than 1% of total revenue for the three and six months ended June 30, 2013 and 2012.

Non-Cash Consulting Expense

From time to time, the Company issues restricted stock awards to consultants and advisors to the Company. These awards are measured at fair value at each reporting date, recognized ratably over the vesting period and are recorded in non-cash consulting expense.

Advertising Costs

The Company expenses advertising costs as incurred. The Company had no Advertising expense in the six months ended June 30, 2013 and $29,000 for the quarter ended June 30, 2012.

Research and Development

Research and development costs, which are principally related to internal costs for the development of new technologies and processes for tissue and coatings, are expensed as incurred.

Income Taxes

The Company accounts for income taxes under the asset and liability method of accounting for deferred taxes as prescribed under FASB ASC 740, Accounting for Income Taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. When applicable, a valuation allowance is established to reduce any deferred tax asset when it is determined that it is more likely than not that some portion of the deferred tax asset will not be realized. ASC 740 also requires reporting of taxes based on tax positions that meet a more-likely-than-not standard and that are measured at the amount that is more-likely-than-not to be realized. Differences between financial and tax reporting which do not meet this threshold are required to be recorded as unrecognized tax benefits. ASC 740 also provides guidance on the presentation of tax matters and the recognition of potential IRS interest and penalties. The Company classifies penalty and interest expense related to income tax liabilities as an income tax expense. There are no significant interest and penalties recognized in the statement of operations or accrued on the balance sheet. See Note 12, “Income Taxes” below.

Long-Lived Assets

Long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. No impairment was recorded during the six months ended June 30, 2013 or 2012.

Net Loss Per Share

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted net income (loss) per share is computed in a manner consistent with that of basic earnings per share while giving effect to all potentially dilutive common shares outstanding during the period, which include the assumed exercise of stock options and warrants using the treasury stock method. Diluted net loss per share was the same as basic net loss per share for the six months ended June 30, 2013 and 2012 and the three months ended June 30, 2013 as shares issuable upon the exercise of stock options and warrants were anti-dilutive as a result of the net losses incurred for those periods. There were 1,988,313 dilutive shares for the three months ended June 30, 2012.

Stock-Based Compensation

The Company records stock-compensation expense according to the provisions of ASC 718. Under ASC 718, stock-based compensation costs are recognized based on the estimated fair value at the grant date for all stock-based awards. The Company estimates grant date fair values using the Black-Scholes-Merton option pricing model, which requires assumptions of the life of the award and the stock price volatility over the term of the award. The Company records compensation cost of stock-based awards using the straight line method, which is recorded into earnings over the vesting period of the award. Pursuant to the income tax provisions included in ASC 718-740, the Company has elected the “short cut method” of computing its hypothetical pool of additional paid-in capital that is available to absorb future tax benefit shortfalls.

Fair Value of Financial Instruments

The carrying values of financial instruments, including trade accounts receivable, accounts payable, other accrued expenses and long-term debt, approximate their fair values based on terms and related interest rates.

We follow a framework for measuring fair value. The framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.

Level 2: Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. During the six months ended June 30, 2013 and 2012, there was no reclassification in financial assets or liabilities between Level 1, 2 or 3 categories.

The following tables set forth by level, within the fair value hierarchy, our assets and liabilities as of June 30, 2013 and December 31, 2012 that are measured at fair value on a recurring basis:

Accrued stock compensation

	As of June 30, 2013		As of December 31, 2012
Level 1	$	82,940	$	218,850
Level 2		-		-
Level 3		-		-

The valuation technique used to measure fair value of the accrued stock compensation is based on quoted stock market prices.

Warrant derivative liability

	As of June 30, 2013		As of December 31, 2012
Level 1		-		-
Level 2		-		-
Level 3	$	1,374,044	$	984,356

Acquisition contingent consideration liability

	As of June 30, 2013		As of December 31, 2012
Level 1		-		-
Level 2		-		-
Level 3	$	-	$	91,740

The valuation technique used to measure fair value of the warrant liability and contingent consideration is based on a lattice model and significant assumptions and inputs determined by us.

Level 3 Changes

The following is a reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ending June 30, 2013:

Warrant derivative liability

Balance at January 1, 2013	$	984,356
Gain recognized in earnings		(1,095,625)
New warrants issued		1,485,313
Balance at June 30, 2013	$	1,374,044

Acquisition contingent consideration liability

Balance at January 1, 2013	$	91,740
Change recognized in earnings		(91,740)
Balance at June 30, 2013	$	-

During the six months ended June 30, 2013, the Company did not change any of the valuation techniques used to measure its liabilities at fair value.

Items measured at fair value on a non-recurring basis:

The Company’s royalty liability is carried at its estimated fair value based upon the discounted present value of the payments using an estimated discount rate. The Company did not have access to a readily traded market for similar credit risks and the estimated interest rate was based upon the Company’s estimate of a market interest rate to obtain similar financing. The Company originally discounted the $16.8 million of estimated payments at an interest rate of 16.7%. This was adjusted to an estimated royalty total of $13.8 million as of December 31, 2012 and was not adjusted in the first six months of 2013. Accordingly, these inputs are classified as Level 3 inputs.

Recent Accounting Pronouncements

There are no recently issued accounting standards for which the Company expects a material impact to its consolidated financial statements.

Equity	6 Months Ended
Equity	Jun. 30, 2013
Equity [Abstract]
Stockholders Equity Note Disclosure [Text Block]	(2) Equity During the first quarter of 2012, we issued 1,475,037 shares of our common stock to Lincoln Park Capital for aggregate proceeds of $3,899,996. We used the proceeds for working capital and general corporate purposes. On June 10, 2013, the Company issued approximately 8.51 million shares of common stock to new and existing investors at a price per share of $0.57, which represented a 10% discount to the closing price on June 4, 2013. For each common share purchased in the offering, investors received a warrant providing the right to purchase 0.5 shares of Bacterin common stock at an exercise price of $0.72, a 15% premium to the June 4, 2013 closing price. The warrants will be exercisable for seven years beginning 6 months from the date of issuance. The transaction resulted in net proceeds to Bacterin International of approximately $4.45 million, after deducting approximately $400,000 of placement agents’ fees and offering expenses. Proceeds from the transaction will be used to fund the Company's operations and working capital requirements.

Acquisition	6 Months Ended
Acquisition	Jun. 30, 2013
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	(3) Acquisition In 2011, the Company acquired the assets of a medical devices company. As part of the purchase agreement, we agreed to pay an additional $500,000 in common stock if gross revenue from the sale of products resulting from the purchased assets equals or exceeds $1 million, and an additional $500,000 in common stock if gross revenue from the sale of products equals or exceeds $2 million, provided that such gross revenue thresholds were achieved within 2 years. The revenue thresholds were not achieved within 2 years of the asset acquisition, so no additional stock issuances are required. The initial valuation of the contingent consideration was based upon management’s estimates of the probability of reaching the milestones that would trigger the requirement to pay the contingent amounts. During 2013, management reviewed and adjusted the assumptions associated with the contingent liability which resulted in an elimination of the contingent liability as of June 30, 2013.

Inventories

6 Months Ended

Jun. 30, 2013

Inventory Disclosure [Abstract]

Inventory Disclosure [Text Block]

(4) Inventories

Inventories consist of the following:

	June 30,		December 31,
	2013		2012
Current inventories
Raw materials	$	2,105,936	$	1,919,250
Work in process		4,239,439		4,991,032
Finished goods		8,473,975		7,350,332
		14,819,350		14,260,614
Reserve		(1,016,287)		(1,119,193)
Current inventories, total	$	13,803,063	$	13,141,421
Non-current inventories
Finished goods	$	1,238,225	$	1,238,225
Non-current inventories, total	$	1,238,225	$	1,238,225
Total inventories	$	15,041,288	$	14,379,646

Property and Equipment, Net

6 Months Ended

Jun. 30, 2013

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

(5) Property and Equipment, Net

Property and equipment, net are as follows:

	June 30,		December 31,
	2013		2012
Buildings	$	1,653,263	$	1,653,263
Equipment		5,740,059		5,172,523
Computer equipment		312,650		312,650
Computer software		395,146		392,206
Furniture and fixtures		170,118		170,118
Leasehold improvements		1,793,756		1,793,756
Vehicles		41,099		78,306
Total cost		10,106,091		9,572,822
Less: accumulated depreciation		(4,647,819)		(4,337,955)
	$	5,458,272	$	5,234,867

The Company leases certain equipment under capital leases. For financial reporting purposes, minimum lease payments relating to the assets have been capitalized. As of June 30, 2013, the Company has recorded $549,604 gross assets in Equipment, and $124,892 of accumulated depreciation relating to assets under capital leases.

Maintenance and repairs expense for the first six months of 2013 and 2012 was $146,422 and $121,350, respectively. Depreciation expense related to property and equipment, including property under capital lease for the first six months of 2013 and 2012 was $357,015 and $364,198, respectively.

Intangible Assets

6 Months Ended

Jun. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets Disclosure [Text Block]

(6) Intangible Assets

Bacterin has applied for various patents with regards to processes for its products.

The following table sets forth information regarding intangible assets:

	June 30, 2013		December 31, 2012
Intellectual Property
Gross carrying value	$	830,927	$	820,778
Accumulated amortization	$	(266,234)	$	(228,400)
Net carrying value	$	564,693	$	592,378

Aggregate amortization expense:	$	37,834	$	74,918

Estimated amortization expense:

Remainder of 2013			$	37,834
2014			$	74,918
2015			$	74,918
2016			$	74,918
2017			$	74,918
Thereafter			$	227,187
Total			$	564,693

Accrued Liabilities

6 Months Ended

Jun. 30, 2013

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

(7) Accrued Liabilities

Accrued liabilities consist of the following:

	June 30,		December 31,
	2013		2012
Acquisition contingent liability	$	-	$	91,740
Accrued stock compensation		82,940		218,850
Wages/commissions payable		1,099,123		1,013,909
Other accrued expenses		1,209,250		1,075,591
	$	2,391,313	$	2,400,090

Long-term Debt

6 Months Ended

Jun. 30, 2013

Debt Disclosure [Abstract]

Long-term Debt [Text Block]

(8) Long-term Debt

On April 23, 2012, the Company secured an accounts receivable credit facility with Midcap Financial LLC and Silicon Valley Bank. The revolving loan credit facility allowed Bacterin to borrow up to $5 million through January 1, 2015. The facility allowed borrowings based upon a predetermined formula of up to 80% of Bacterin's eligible accounts receivable, as defined in the credit and security agreement. The Company also amended its existing Loan and Security Agreement with MidCap to allow the Company to borrow up to an additional $3 million for the next nine months in connection with a permitted acquisition. The credit facility carried an interest rate of LIBOR plus 4%, subject to a LIBOR floor rate of 2.5%. The Company also agreed to pay a 0.5% collateral management fee on the average outstanding balance of the facility and 1% of the average unused portion of the facility, as well as a 1% origination fee. We repaid the outstanding balance owed on this credit facility in full with the proceeds from our credit facility with ROS Acquisition Offshore LP (“ROS”) on August 24, 2012.

On August 24, 2012, the Company entered into a Credit Agreement with ROS, whereby ROS agreed to provide an initial $20 million term loan and Bacterin may also borrow an additional $5 million upon achievement of certain revenue objectives prior to December 31, 2013. The loan carries an interest rate of LIBOR plus 12.13%, subject to a LIBOR floor rate of 1.0%. Bacterin also agreed to pay a royalty of 1.75% on the first $45,000,000 of net sales, plus 1.0% of net sales in excess of $45,000,000 for each of the next ten years. Bacterin has the right to repay the loan and royalty interest at amounts to be determined based on the date of repayment and the amount of prior principal, interest and royalty payments. The loan is secured by substantially all of our assets. The estimate of the royalty component of the facility over the life of the agreement resulted in a debt discount and a royalty liability of $7,341,520. The debt discount will be amortized to interest expense over the seven year term of the loan using the effective interest method. The royalty liability will be accreted to $13.8 million through interest expense over the ten year term of the royalty agreement using the effective interest method. Payments made under the royalty agreement, per the table below, will directly reduce the royalty liability.

The Company received net proceeds of approximately $10 million following repayment of the existing term loan and accounts receivable credit facility with MidCap Financial, including prepayment penalties. The Company plans to use the net proceeds for working capital and general corporate purposes.

On May 16, 2013, we entered into an amendment to our Credit Agreement with ROS, whereby ROS agreed to reduce our minimum liquidity requirement from $1,500,000 to $750,000 until September 30, 2013. In exchange, we agreed to pay a fee of $300,000 required to be paid pursuant to the Credit Agreement or other loan documents which is recorded in Long-term debt and in Other long term assets which will be amortized to interest expense over the term of the debt.

There were two compliance violations of covenants related to the ROS agreement in the second quarter of 2013. The Company did not achieve the $8.5 million revenue in the second quarter of 2013 for which we received a waiver in exchange for an additional fee as discussed in Note 15, “Subsequent Events” below. In addition, the Company did not hire a Chief Executive Officer with 90 days of the resignation of the prior Chief Executive Officer for which we received a waiver in exchange for Board observer rights.

Long-term debt consists of the following:

	June 30, 2013		December 31, 2012
Loan payable to ROS Acquisition Offshore, LIBOR plus 12.13% maturing August 2019	$	20,000,000	$	20,000,000
Adjustment fee payable to ROS Acquisition Offshore August 2019		300,000		-
6.00% loan payable to Valley Bank of Belgrade, $10,746 monthly payments including interest, maturing December 24, 2030; secured by building		1,398,568		1,421,420
		21,698,568		21,421,420

Less: Current portion		(46,320)		(45,135)
Debt discount		(6,310,002)		(6,893,183)
Long-term debt	$	15,342,246	$	14,483,102

The following is a summary of maturities due on the debt as of June 30, 2013:

Remainder of 2013		22,813
2014		47,727
2015		50,670
2016		1,720,463
2017		6,723,781
Thereafter		13,133,114
Total	$	21,698,568

The following is a summary of estimated future royalty payments as of June 30, 2013:

Remainder of 2013		394,000
2014		853,000
2015		1,050,000
2016		1,289,000
2017		1,384,000
Thereafter		8,477,000
Total	$	13,447,000

Stock-Based Compensation

6 Months Ended

Jun. 30, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

(9) Stock-Based Compensation

Our Equity Incentive Plan ("The Plan") provides for stock awards, including options and performance stock awards, to be granted to employees, consultants, independent contractors, officers and directors. The purpose of the Plan is to enable us to attract, retain and motivate key employees, directors and, on occasion, independent consultants, by providing them with stock options and restricted stock grants. Stock options granted under the Plan may be either incentive stock options to employees, as defined in Section 422A of the Internal Revenue Code of 1986, or non-qualified stock options. The Plan is administered by the compensation committee of our Board of Directors. The administrator of the Plan has the power to determine the terms of any stock options granted under the Plan, including the exercise price, the number of shares subject to the stock option and conditions of exercise. Stock options granted under the Plan are generally not transferable, vest in installments over the requisite service period and are exercisable during the stated contractual term of the option only by such optionee. The exercise price of all incentive stock options granted under the Plan must be at least equal to the fair market value of the shares of common stock on the date of the grant. 9 million shares are authorized under the Plan and at June 30, 2013, we had approximately 808,648 shares available for issuance. Shares issued under the Plan may be authorized, but unissued, or reacquired shares.

Stock compensation expense recognized in the statement of operations for the six months ended June 30, 2013 and 2012 is based on awards ultimately expected to vest and reflects an estimate of awards that will be forfeited. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

The estimated fair value of stock options granted is done using the Black-Sholes-Merton method applied to individual grants. The Company utilizes historical employee termination behavior to determine the estimated forfeiture rates. If the actual forfeitures differ from those estimated by management, adjustments to compensation expense will be made in future periods. An assumed forfeiture rate of 20.00% was used for the first six months of 2013.

Key assumptions used to estimate the fair value of stock awards are as follows:

· Risk-Free Rate: The risk-free rate is determined by reference to U.S. Treasury yields at or near the time of grant for time periods similar to the expected term of the award. We used a weighted-average rate of 1.12% for the six months ended June 30, 2013.

· Expected Term: We do not have adequate history to estimate an expected term of stock-based awards, and accordingly, we use the short-cut method as prescribed by Staff Accounting Bulletin 107 to determine an expected term. We used a weighted-average expected term of 5.86 years for the six months ended June 30, 2013.

· Volatility: We estimate expected volatility based on peer-companies as prescribed by ASC 718. We used a weighted-average volatility rate of 63% for the six months ended June 30, 2013.

· Dividend Yield: The dividend yield assumption is based on our history and expectation of dividend payouts and was 0% for the six months ended June 30, 2013.

Activity under our stock option plans was as follows:

	2013						2012
	Shares		Weighted Average Exercise Price		Weighted Average Fair Value at Grant Date		Shares		Weighted Average Exercise Price		Weighted Average Fair Value at Grant Date
Outstanding at January 1		5,266,535	$	2.02	$	1.03		4,828,910	$	2.14	$	1.01
Granted		1,281,250		0.70		0.50		820,625		2.15		1.05
Exercised		-		-		-		(15,000)		1.34		0.45
Cancelled or expired		(530,000)		1.79		0.87		(1,038,750)		1.92		0.91
Outstanding at June 30		6,017,785	$	1.75	$	0.94		4,595,785	$	2.19	$	1.04
Exercisable at June 30		2,659,701	$	1.86	$	0.86		2,028,993	$	1.71	$	0.72

The aggregate intrinsic value of options outstanding as of June 30, 2013 is $500,141. The aggregate intrinsic value of exercisable options as of June 30, 2013 is $300,666. As of June 30, 2013, there were 3,358,084 unvested options with a weighted average fair value at the grant date of $0.98 per option. As of June 30, 2013, there is $199,475 compensation expense related to nonvested awards not yet recognized.

From time to time we may grant stock options and restricted stock grants to consultants. We account for consultant stock options in accordance with ASC 505-50. Consulting expense for the grant of stock options to consultants is determined based on the estimated fair value of the stock options at the measurement date as defined in ASC 505-50 and is recognized over the vesting period.

The following table summarizes restricted stock award activity during the period ended June 30, 2013:

	Shares
Outstanding at Jan. 1, 2013		733,900
Awarded		-
Cancelled		(112,500)
Vested		(142,000)
Outstanding at June 30, 2013		479,400

The restricted stock awards generally vest over three to five year periods. The Company recognized reduction of non-cash consulting expense of $31,229 for the first six months of 2013 and expense of $304,184 for the six months ended June 30, 2012. As of June 30, 2013, the total expense related to nonvested restricted stock awards not yet recognized is $131,769 and is expected to be recognized over three years.

Warrants

6 Months Ended

Jun. 30, 2013

Other Equity Transactions [Abstract]

Other Equity Transactions [Text Block]

(10) Warrants

In the fourth quarter of 2012, the Company issued 297,991 warrants with an exercise price of $2.30 to a broker in conjunction with the August 24, 2012 financing arrangement with ROS. These were recorded in “Other Assets” and will be amortized over the life of the financing term. In addition, on July 23, 2012 the Company issued 300,895 warrants with an exercise price of $1.03 to a private party resulting in $342,485 recorded in “Other Expense”.

The following table summarizes our warrant activities for the six months ended June 30, 2013:

			Weighted
			Average
			Exercise
	Shares		Price
Outstanding at January 1, 2013		7,321,667	$	2.20
Issued		4,352,215		0.57
Exercised		-		-
Expired		(533,173)		2.00
Outstanding at June 30, 2013		11,140,709	$	1.57

We utilize a lattice model to determine the fair market value of the warrants accounted for as liabilities. The 1,570,565 warrants issued in connection with a 2010 bridge financing, the 375,000 warrants issued in connection with a 2010 debt financing and the 4,254,387 warrants issued in connection with the second quarter 2013 equity financing were accounted for as derivative liabilities in connection with the price protection provisions of the warrants in compliance with ASC 815. The warrants issued in the second quarter of 2013 resulted in a warrant derivative liability of $1,485,313 as of the issuance on June 5, 2013. There were an additional 143,700 warrants in the first quarter of 2012 as a result of the LPC share issuance triggering the anti-dilution clause in the original warrant agreement and an additional 97,828 related to the second quarter of 2013 equity financing. The lattice model accommodates the probability of exercise price adjustment features as outlined in the warrant agreements. We recorded an unrealized gain of $1,095,625 resulting from the change in the fair value of the warrant derivative liability for the first six months of 2013. Under the terms of the warrant agreement, at any time while the warrant is outstanding, the exercise price per share can be reduced to the price per share of future subsequent equity sales of our common stock or common stock equivalents that is lower than the exercise price per share as stated in the warrant agreement.

The estimated fair value was derived using the lattice model with the following weighted-average assumptions:

	Three months ended
	June 30,
	2013			2012
Value of underlying common stock (per share)	$	0.45		$	1.34
Risk free interest rate		0.72	%		0.38	%
Expected term		6.21 years			4.35 years
Dividend yield		0	%		0	%
Volatility		63	%		65	%

The following table summarizes our activities related to number of warrants used in the derivative liability for the six months ended June 30, 2013 and 2012:

	2013		2012
Balance at January 1		1,649,707		1,506,007
Derivative warrants issued		4,352,215		143,700
Derivative warrants exercised		-		-
Balance at June 30		6,001,922		1,649,707

Commitments and Contingencies

6 Months Ended

Jun. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

(11) Commitments and Contingencies

Operating Leases

We lease two office facilities under non-cancelable operating lease agreements with expiration dates in 2013 and 2019. We have the option to extend both the leases for another ten year term and for one facility, we have the right of first refusal on any sale. We lease an additional office facility under a month-to-month arrangement. Future minimum payments for the next five years and thereafter as of June 30, 2013, under these leases, are as follows:

Remainder of 2013	$	122,414
2014	$	270,993
2015	$	263,136
2016	$	263,136
2017	$	263,136
Thereafter	$	852,769
Total	$	2,035,584

Rent expense was approximately $128,000 and $143,000 for the six months ended June 30, 2013 and 2012, respectively. Rent expense is determined using the straight-line method of the minimum expected rent paid over the term of the agreement. We have no contingent rent agreements.

Indemnifications

Our arrangements generally include limited warranties and certain provisions for indemnifying customers against liabilities if our products or services infringe a third-party's intellectual property rights. To date, we have not incurred any material costs as a result of such warranties or indemnifications and have not accrued any liabilities related to such obligations in the accompanying financial statements.

We have also agreed to indemnify our directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person's service as a director or officer, including any action by us, arising out of that person's services as our director or officer or that person's services provided to any other company or enterprise at our request.

Litigation

On April 4, 2012, Bacterin International, Inc. filed suit in the United States District Court of the Eastern District of Pennsylvania against SeaArk Capital, LLC and its principal, Mark Bartosh, seeking recovery of $1,648,993.58 for product delivered to SeaArk in 2011. In connection with this litigation, Bacterin also filed a motion for a prejudgment writ of replevin or attachment in the Third Judicial District Court in the State of Utah to recover product previously sold to SeaArk. The Utah case was removed to the United States District Court for the District of Utah and Bacterin’s motion for prejudgment writ was granted. SeaArk has returned all Bacterin products previously stored in Utah. On June 28, 2013, the parties entered into a settlement agreement whereby SeaArk agreed to (i) pay for all Bacterin products previously sold by SeaArk; (ii) return all Bacterin products located in the United States; and (iii) pay Bacterin sixty percent of the proceeds from sales of Bacterin products located in Puerto Rico.

On January 29, 2013, we received two warning letters from the Food and Drug Administration (“FDA”) related to our procedures to ensure compliance with regulatory requirements. We responded to the warning letters and on April 17, 2013 we received two letters from FDA in which the agency stated that it was in receipt of our response letters and found that the corrective actions in those letters appeared to be adequate. The letters stated that the corrections will be further evaluated in conjunction with our operations during the next inspection of our facilities. FDA conducted an inspection of our facilities in July 2013, at the conclusion of which FDA issued two Form FDA 483s with one inspectional observation regarding our procedures for product handling and two inspectional observations related to aseptic techniques. We are committed to actively working with FDA to address their concerns.

On February 11, 2013, we received a subpoena from the Office of the Inspector General of the U.S. Department of Health and Human Services (“OIG”) in connection with an investigation into possible false or otherwise improper claims submitted to Medicare. The subpoena requests documents related to physician referral programs operated by the Company, which we believe refers to the Company’s prior practice of compensating physicians for performing certain educational and promotional services on behalf of the Company. This program was discontinued in 2010 and involved payments to only a small number of physicians that we believe were made in accordance with all applicable laws. We submitted our initial production of documents in March 2013 and have not received any further requests or correspondence from the OIG.

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2013
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	(12) Income Taxes In evaluating the realizability of the net deferred tax assets, we take into account a number of factors, primarily relating to the ability to generate taxable income. Where it is determined that it is likely that we will be unable to realize deferred tax assets, a valuation allowance is established against the portion of the deferred tax asset. Because it cannot be accurately determined when or if we will become profitable, a valuation allowance was provided against the entire deferred income tax asset balance. The 2008 through 2012 tax years remain open to examination by the Internal Revenue Service and the 2006 to 2012 tax years remain open to the Montana Department of Revenue. These taxing authorities have the authority to examine those tax years until the applicable statute of limitations expire. The Company did not recognize any interest or penalties related to income taxes for the six months ended June 30, 2013 and 2012.

Supplemental Disclosure of Cash Flow Information

6 Months Ended

Jun. 30, 2013

Supplemental Cash Flow Elements [Abstract]

Cash Flow, Supplemental Disclosures [Text Block]

(13) Supplemental Disclosure of Cash Flow Information

Supplemental cash flow information is as follows:

	Six months ended
	June 30,
	2013		2012
Supplemental disclosure of cash flow information
Cash paid during the period for:
Interest	$	2,238,636	$	483,336
Income taxes		-		-
Non-cash activities:
ROS adjustment fee	$	300,000	$	-
Settlement of SeaArk accounts receivable	$	1,829,647	$	-
Inventory received in SeaArk settlement	$	409,838	$	-
Write-off of SeaArk allowance for doubtful accounts	$	1,419,809	$	-
Net shares issued for non-cash consulting expense	$	143,011	$	-
Capital lease acquisition	$	-	$	177,507

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2013
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	(14) Related Party Transactions Guy Cook, our former President and Chief Executive Officer, serves as a board member of West Coast Tissue Services (“WCTS”) and formerly served as a director for American Donor Services (“ADS”). Mr. Cook had not received any compensation for his board service for either entity as of the date of his resignation. Mitchell Godfrey, a director, is on the board of ADS and also serves as secretary and treasurer for ADS. Mr. Godfrey receives $5,000 annually for his service to ADS. ADS and WCTS recover tissue from donors. We reimburse them for their recovery fees, which are comprised primarily of labor costs. The approximate aggregate amount of all transactions with WCTS for the first six months of 2013 and 2012 was $337,900 and $200,700, respectively, and the approximate aggregate amount of all transactions with ADS for the first six months of 2013 and 2012 was $909,120 and $569,911, respectively. These relationships benefit us as these entities provide us with donors, thus insuring that we have a pipeline of current and future donors, which is necessary to our success. As of June 30, 2013, we had an accounts payable balance of $478,762 to American Donor Services. On June 27, 2012, the Board of Directors granted a waiver of certain provisions of the Company’s Code of Conduct to allow an entity controlled by two of our former CEO’s adult children to become a distributor of the Company’s products. This entity acquired inventory from Allograft Tissue Management, a non-affiliated distributor that had previously acquired inventory from the Company. The affiliated distributor, Silver Forest Fund, LP, exchanged products initially purchased from the non-affiliated distributor with Bacterin for different Bacterin products of equivalent value. Other than product exchanges and payment of amounts owed by the non-affiliated distributor, there have been no other direct transactions between Bacterin and the affiliated distributor. Mr. Cook pledged 1,850,000 of his shares of Bacterin stock as collateral for loans made to the affiliated distributor by independent third parties. On April 5, 2013, Guy Cook resigned from his roles of Chief Executive Officer, President and Chairman of the Board effective immediately. The Board unanimously voted to have Kent Swanson, an existing independent director, serve as Acting Chairman of the Board. Our current Chief Financial Officer, John Gandolfo, and our Chief Operating Officer, Darrel Holmes, will jointly serve as interim Co-Chief Executive Officers until the Board appoints a new Chief Executive Officer.

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2013
Subsequent Events [Abstract]
Subsequent Events [Text Block]	(15) Subsequent Events On August 7, 2013, the Company announced that Daniel Goldberger has agreed to become the Company’s new Chief Executive Officer. On August 12, 2013, the Company received a waiver from ROS for failure to achieve $8.5 million of revenue in the second quarter of 2013. In exchange for the waiver, the Company agreed to pay a fee of $400,000 when the Company pays, prepays or is required to pay any principal amount of the loan.

Business Description and Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Description [Policy Text Block]

Business Description

Bacterin’s device division develops and licenses coatings for various medical device applications.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentrations and Credit Risk

Revenue by geographical region is as follows:

	Six months ended June 30,
	2013		2012
United States	$	16,562,064	$	15,507,794
Rest of World		323,591		470,479
	$	16,885,655	$	15,978,273

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

Receivables, Policy [Policy Text Block]

Accounts Receivable

Accounts Payable Related Party Policy [Policy Text Block]

Accounts Payable - Related Party

Accounts payable to a related party includes amounts due to American Donor Services, a supplier of donors to the Company. See Note 14, “Related Party Transactions” below.

Inventory, Policy [Policy Text Block]

Inventories

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Goodwill

Derivatives, Reporting of Derivative Activity [Policy Text Block]

Derivative Instruments

Intangible Assets, Finite-Lived, Policy [Policy Text Block]

Intangible Assets

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Non Cash Consulting Expense [Policy Text Block]

Non-Cash Consulting Expense

Advertising Costs, Policy [Policy Text Block]

Advertising Costs

The Company expenses advertising costs as incurred. The Company had no Advertising expense in the six months ended June 30, 2013 and $29,000 for the quarter ended June 30, 2012.

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Research and development costs, which are principally related to internal costs for the development of new technologies and processes for tissue and coatings, are expensed as incurred.

Income Tax, Policy [Policy Text Block]

Income Taxes

Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]

Long-Lived Assets

Earnings Per Share, Policy [Policy Text Block]

Net Loss Per Share

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Stock-Based Compensation

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The following tables set forth by level, within the fair value hierarchy, our assets and liabilities as of June 30, 2013 and December 31, 2012 that are measured at fair value on a recurring basis:

Accrued stock compensation

	As of June 30, 2013		As of December 31, 2012
Level 1	$	82,940	$	218,850
Level 2		-		-
Level 3		-		-

The valuation technique used to measure fair value of the accrued stock compensation is based on quoted stock market prices.

Warrant derivative liability

	As of June 30, 2013		As of December 31, 2012
Level 1		-		-
Level 2		-		-
Level 3	$	1,374,044	$	984,356

Acquisition contingent consideration liability

	As of June 30, 2013		As of December 31, 2012
Level 1		-		-
Level 2		-		-
Level 3	$	-	$	91,740

The valuation technique used to measure fair value of the warrant liability and contingent consideration is based on a lattice model and significant assumptions and inputs determined by us.

Level 3 Changes

Warrant derivative liability

Balance at January 1, 2013	$	984,356
Gain recognized in earnings		(1,095,625)
New warrants issued		1,485,313
Balance at June 30, 2013	$	1,374,044

Acquisition contingent consideration liability

Balance at January 1, 2013	$	91,740
Change recognized in earnings		(91,740)
Balance at June 30, 2013	$	-

During the six months ended June 30, 2013, the Company did not change any of the valuation techniques used to measure its liabilities at fair value.

Items measured at fair value on a non-recurring basis:

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

There are no recently issued accounting standards for which the Company expects a material impact to its consolidated financial statements.

Business Description and Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule Of Concentration Of Risk Revenue By Geographical Region [Table Text Block]

Revenue by geographical region is as follows:

	Six months ended June 30,
	2013		2012
United States	$	16,562,064	$	15,507,794
Rest of World		323,591		470,479
	$	16,885,655	$	15,978,273

Schedule Of Accrued Stock Compensation [Table Text Block]

The following tables set forth by level, within the fair value hierarchy, our assets and liabilities as of June 30, 2013 and December 31, 2012 that are measured at fair value on a recurring basis:

Accrued stock compensation

	As of June 30, 2013		As of December 31, 2012
Level 1	$	82,940	$	218,850
Level 2		-		-
Level 3		-		-

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

The valuation technique used to measure fair value of the accrued stock compensation is based on quoted stock market prices.

Warrant derivative liability

	As of June 30, 2013		As of December 31, 2012
Level 1		-		-
Level 2		-		-
Level 3	$	1,374,044	$	984,356

Acquisition contingent consideration liability

	As of June 30, 2013		As of December 31, 2012
Level 1		-		-
Level 2		-		-
Level 3	$	-	$	91,740

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

Warrant derivative liability

Balance at January 1, 2013	$	984,356
Gain recognized in earnings		(1,095,625)
New warrants issued		1,485,313
Balance at June 30, 2013	$	1,374,044

Acquisition contingent consideration liability

Balance at January 1, 2013	$	91,740
Change recognized in earnings		(91,740)
Balance at June 30, 2013	$	-

Inventories (Tables)

6 Months Ended

Jun. 30, 2013

Inventory Disclosure [Abstract]

Schedule Of Inventory [Table Text Block]

Inventories consist of the following:

	June 30,		December 31,
	2013		2012
Current inventories
Raw materials	$	2,105,936	$	1,919,250
Work in process		4,239,439		4,991,032
Finished goods		8,473,975		7,350,332
		14,819,350		14,260,614
Reserve		(1,016,287)		(1,119,193)
Current inventories, total	$	13,803,063	$	13,141,421
Non-current inventories
Finished goods	$	1,238,225	$	1,238,225
Non-current inventories, total	$	1,238,225	$	1,238,225
Total inventories	$	15,041,288	$	14,379,646

Property and Equipment, Net (Tables)

6 Months Ended

Jun. 30, 2013

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Property and equipment, net are as follows:

	June 30,		December 31,
	2013		2012
Buildings	$	1,653,263	$	1,653,263
Equipment		5,740,059		5,172,523
Computer equipment		312,650		312,650
Computer software		395,146		392,206
Furniture and fixtures		170,118		170,118
Leasehold improvements		1,793,756		1,793,756
Vehicles		41,099		78,306
Total cost		10,106,091		9,572,822
Less: accumulated depreciation		(4,647,819)		(4,337,955)
	$	5,458,272	$	5,234,867

Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets [Table Text Block]

The following table sets forth information regarding intangible assets:

	June 30, 2013		December 31, 2012
Intellectual Property
Gross carrying value	$	830,927	$	820,778
Accumulated amortization	$	(266,234)	$	(228,400)
Net carrying value	$	564,693	$	592,378

Aggregate amortization expense:	$	37,834	$	74,918

Estimated amortization expense:

Remainder of 2013			$	37,834
2014			$	74,918
2015			$	74,918
2016			$	74,918
2017			$	74,918
Thereafter			$	227,187
Total			$	564,693

Accrued Liabilities (Tables)

6 Months Ended

Jun. 30, 2013

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued liabilities consist of the following:

	June 30,		December 31,
	2013		2012
Acquisition contingent liability	$	-	$	91,740
Accrued stock compensation		82,940		218,850
Wages/commissions payable		1,099,123		1,013,909
Other accrued expenses		1,209,250		1,075,591
	$	2,391,313	$	2,400,090

Long-term Debt (Tables)

6 Months Ended

Jun. 30, 2013

Debt Disclosure [Abstract]

Schedule of Debt [Table Text Block]

Long-term debt consists of the following:

	June 30, 2013		December 31, 2012
Loan payable to ROS Acquisition Offshore, LIBOR plus 12.13% maturing August 2019	$	20,000,000	$	20,000,000
Adjustment fee payable to ROS Acquisition Offshore August 2019		300,000		-
6.00% loan payable to Valley Bank of Belgrade, $10,746 monthly payments including interest, maturing December 24, 2030; secured by building		1,398,568		1,421,420
		21,698,568		21,421,420

Less: Current portion		(46,320)		(45,135)
Debt discount		(6,310,002)		(6,893,183)
Long-term debt	$	15,342,246	$	14,483,102

Schedule of Maturities of Long-term Debt [Table Text Block]

The following is a summary of maturities due on the debt as of June 30, 2013:

Remainder of 2013		22,813
2014		47,727
2015		50,670
2016		1,720,463
2017		6,723,781
Thereafter		13,133,114
Total	$	21,698,568

Schedule Of Royalty Payments [Table Text Block]

The following is a summary of estimated future royalty payments as of June 30, 2013:

Remainder of 2013		394,000
2014		853,000
2015		1,050,000
2016		1,289,000
2017		1,384,000
Thereafter		8,477,000
Total	$	13,447,000

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

Activity under our stock option plans was as follows:

	2013						2012
	Shares		Weighted Average Exercise Price		Weighted Average Fair Value at Grant Date		Shares		Weighted Average Exercise Price		Weighted Average Fair Value at Grant Date
Outstanding at January 1		5,266,535	$	2.02	$	1.03		4,828,910	$	2.14	$	1.01
Granted		1,281,250		0.70		0.50		820,625		2.15		1.05
Exercised		-		-		-		(15,000)		1.34		0.45
Cancelled or expired		(530,000)		1.79		0.87		(1,038,750)		1.92		0.91
Outstanding at June 30		6,017,785	$	1.75	$	0.94		4,595,785	$	2.19	$	1.04
Exercisable at June 30		2,659,701	$	1.86	$	0.86		2,028,993	$	1.71	$	0.72

Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]

The following table summarizes restricted stock award activity during the period ended June 30, 2013:

	Shares
Outstanding at Jan. 1, 2013		733,900
Awarded		-
Cancelled		(112,500)
Vested		(142,000)
Outstanding at June 30, 2013		479,400

Warrants (Tables)

6 Months Ended

Jun. 30, 2013

Other Equity Transactions [Abstract]

Schedule Of Warrant Activity [Table Text Block]

The following table summarizes our warrant activities for the six months ended June 30, 2013:

			Weighted
			Average
			Exercise
	Shares		Price
Outstanding at January 1, 2013		7,321,667	$	2.20
Issued		4,352,215		0.57
Exercised		-		-
Expired		(533,173)		2.00
Outstanding at June 30, 2013		11,140,709	$	1.57

Schedule Of Warrant Valuation Assumptions [Table Text Block]

The estimated fair value was derived using the lattice model with the following weighted-average assumptions:

	Three months ended
	June 30,
	2013			2012
Value of underlying common stock (per share)	$	0.45		$	1.34
Risk free interest rate		0.72	%		0.38	%
Expected term		6.21 years			4.35 years
Dividend yield		0	%		0	%
Volatility		63	%		65	%

Schedule Of Warrants Activities Used In Derivative Liability [Table Text Block]

The following table summarizes our activities related to number of warrants used in the derivative liability for the six months ended June 30, 2013 and 2012:

	2013		2012
Balance at January 1		1,649,707		1,506,007
Derivative warrants issued		4,352,215		143,700
Derivative warrants exercised		-		-
Balance at June 30		6,001,922		1,649,707

Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

Future minimum payments for the next five years and thereafter as of June 30, 2013, under these leases, are as follows:

Remainder of 2013	$	122,414
2014	$	270,993
2015	$	263,136
2016	$	263,136
2017	$	263,136
Thereafter	$	852,769
Total	$	2,035,584

Supplemental Disclosure of Cash Flow Information (Tables)

6 Months Ended

Jun. 30, 2013

Supplemental Cash Flow Elements [Abstract]

Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]

Supplemental cash flow information is as follows:

	Six months ended
	June 30,
	2013		2012
Supplemental disclosure of cash flow information
Cash paid during the period for:
Interest	$	2,238,636	$	483,336
Income taxes		-		-
Non-cash activities:
ROS adjustment fee	$	300,000	$	-
Settlement of SeaArk accounts receivable	$	1,829,647	$	-
Inventory received in SeaArk settlement	$	409,838	$	-
Write-off of SeaArk allowance for doubtful accounts	$	1,419,809	$	-
Net shares issued for non-cash consulting expense	$	143,011	$	-
Capital lease acquisition	$	-	$	177,507

Business Description and Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Fair Value, Concentration of Risk [Line Items]
Total Revenues	$ 8,266,848	$ 8,208,272	$ 16,885,655	$ 15,978,273
United States [Member]
Fair Value, Concentration of Risk [Line Items]
Total Revenues			16,562,064	15,507,794
Rest Of World [Member]
Fair Value, Concentration of Risk [Line Items]
Total Revenues			$ 323,591	$ 470,479

Business Description and Summary of Significant Accounting Policies (Details 1) (USD $)	Jun. 30, 2013	Dec. 31, 2012
fair value on a recurring basis [Line Items]
Accrued stock compensation	$ 82,940	$ 218,850
Fair Value, Inputs, Level 1 [Member]
fair value on a recurring basis [Line Items]
Accrued stock compensation	82,940	218,850
Fair Value, Inputs, Level 2 [Member]
fair value on a recurring basis [Line Items]
Accrued stock compensation	0	0
Fair Value, Inputs, Level 3 [Member]
fair value on a recurring basis [Line Items]
Accrued stock compensation	$ 0	$ 0

Business Description and Summary of Significant Accounting Policies (Details 2) (USD $)	Jun. 30, 2013	Dec. 31, 2012
fair value on a recurring basis [Line Items]
Warrant derivative liability	$ 1,374,044	$ 984,356
Fair Value, Inputs, Level 1 [Member]
fair value on a recurring basis [Line Items]
Warrant derivative liability	0	0
Fair Value, Inputs, Level 2 [Member]
fair value on a recurring basis [Line Items]
Warrant derivative liability	0	0
Fair Value, Inputs, Level 3 [Member]
fair value on a recurring basis [Line Items]
Warrant derivative liability	$ 1,374,044	$ 984,356

Business Description and Summary of Significant Accounting Policies (Details 3) (USD $)	Jun. 30, 2013	Dec. 31, 2012
fair value on a recurring basis [Line Items]
Acquisition contingent consideration liability	$ 0	$ 91,740
Fair Value, Inputs, Level 1 [Member]
fair value on a recurring basis [Line Items]
Acquisition contingent consideration liability	0	0
Fair Value, Inputs, Level 2 [Member]
fair value on a recurring basis [Line Items]
Acquisition contingent consideration liability	0	0
Fair Value, Inputs, Level 3 [Member]
fair value on a recurring basis [Line Items]
Acquisition contingent consideration liability	$ 0	$ 91,740

Business Description and Summary of Significant Accounting Policies (Details 4) (USD $)	6 Months Ended
	Jun. 30, 2013
Warrant Derivative Liabilities [Member]
fair value on a recurring basis [Line Items]
Balance at January 1, 2013	$ 984,356
Gain recognized in earnings	(1,095,625)
New warrants issued	1,485,313
Balance at June 30, 2013	1,374,044
Acquisition Contingent Consideration Liability [Member]
fair value on a recurring basis [Line Items]
Balance at January 1, 2013	91,740
Gain recognized in earnings	(91,740)
Balance at June 30, 2013	$ 0

Business Description and Summary of Significant Accounting Policies (Details Textual) (USD $)	3 Months Ended	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Accounting Policies [Line Items]
Advertising Expense		$ 0	$ 29,000
Discount Of Estimated Payments		16,800,000
Discount Of Estimated Payments Interest Rate		16.70%
Royalty Revenue Percentage		1.00%	1.00%
Future Royalty Liability		$ 13,800,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,988,313
Other Intangible Assets [Member]
Accounting Policies [Line Items]
Estimable useful lives		15 years
Customer Lists [Member]
Accounting Policies [Line Items]
Estimable useful lives		5 years
Building [Member]
Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life		30 years
Computers and Equipment [Member] \| Minimum [Member]
Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life		3 years
Computers and Equipment [Member] \| Maximum [Member]
Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life		7 years
Geographic Concentration Risk [Member]
Accounting Policies [Line Items]
Concentration Risk, Percentage		98.00%	97.00%
Customer Concentration Risk [Member]
Accounting Policies [Line Items]
Concentration Risk, Percentage		8.00%	7.00%
Accounts Receivable Percentage		15.00%	21.00%

Equity (Details Textual) (USD $)	3 Months Ended		6 Months Ended
Equity (Details Textual) (USD $)	Jun. 30, 2013	Mar. 31, 2012	Jun. 30, 2013
Schedule of Equity Method Investments [Line Items]
Stock issued	$ 8,510,000	$ 3,899,996
Stock issued (in shares)		1,475,037
Stock Issued During Period, Price Per Share	$ 0.57
Stock Issued During Period, Percentage Of Discount Based On 4June2013 Closing Price	10.00%
Warrants Issued In Offering, Right To Acquire Common Shares Per Warrant	0.5
Warrants Issued In Offering, Exercise Price	$ 0.72
Warrant Issued In Offering, Percentage Of Premium Based On 4June2013 Closing Price			15.00%
Exercise Term Of Warrants	The warrants will be exercisable for seven years beginning 6 months from the date of issuance
Proceeds from Issuance or Sale of Equity, Total	4,450,000
Payments of Stock Issuance Costs	$ 400,000

Acquisition (Details Textual) (USD $)	6 Months Ended
Acquisition (Details Textual) (USD $)	Jun. 30, 2013
Business Acquisition [Line Items]
Business Acquisition Gross Revenue Achievement Period	2 years
Gross Revenue Equals Or Exceeds One Million [Member]
Business Acquisition [Line Items]
Business Acquisition Additional Equity Interest Issued Or Issuable Value Assigned	$ 500,000
Business Acquisition Gross Revenue	1,000,000
Gross Revenue Equals Or Exceeds Two Million [Member]
Business Acquisition [Line Items]
Business Acquisition Additional Equity Interest Issued Or Issuable Value Assigned	500,000
Business Acquisition Gross Revenue	$ 2,000,000

Inventories (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Current inventories
Raw materials	$ 2,105,936	$ 1,919,250
Work in process	4,239,439	4,991,032
Finished goods	8,473,975	7,350,332
Inventory, Gross	14,819,350	14,260,614
Reserve	(1,016,287)	(1,119,193)
Current inventories, total	13,803,063	13,141,421
Non-current inventories
Finished goods	1,238,225	1,238,225
Non-current inventories, total	1,238,225	1,238,225
Total inventories	$ 15,041,288	$ 14,379,646

Property and Equipment, Net (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Total cost	$ 10,106,091	$ 9,572,822
Less: accumulated depreciation	(4,647,819)	(4,337,955)
Property and equipment, net	5,458,272	5,234,867
Building [Member]
Property, Plant and Equipment [Line Items]
Total cost	1,653,263	1,653,263
Equipment [Member]
Property, Plant and Equipment [Line Items]
Total cost	5,740,059	5,172,523
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total cost	312,650	312,650
Computer software[Member]
Property, Plant and Equipment [Line Items]
Total cost	395,146	392,206
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total cost	170,118	170,118
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total cost	1,793,756	1,793,756
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Total cost	$ 41,099	$ 78,306

Property and Equipment, Net (Details Textual) (USD $)	6 Months Ended
Property and Equipment, Net (Details Textual) (USD $)	Jun. 30, 2013	Jun. 30, 2012
Property, Plant and Equipment [Line Items]
Cost of Property Repairs and Maintenance	$ 146,422	$ 121,350
Depreciation	357,015	364,198
Equipment [Member]
Property, Plant and Equipment [Line Items]
Capital Leased Assets, Gross	549,604
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation	$ 124,892

Intangible Assets (Details) (USD $)	6 Months Ended	12 Months Ended
Intangible Assets (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Intellectual Property
Gross carrying value	$ 830,927	$ 820,778
Accumulated amortization	(266,234)	(228,400)
Net carrying value	564,693	592,378
Aggregate amortization expense:	37,834	74,918
Estimated amortization expense:
Remainder of 2013		37,834
2014		74,918
2015		74,918
2016		74,918
2017		74,918
Thereafter		227,187
Total		$ 564,693

Accrued Liabilities (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Accrued Liabilities [Line Items]
Acquisition contingent liability	$ 0	$ 91,740
Accrued stock compensation	82,940	218,850
Wages/commissions payable	1,099,123	1,013,909
Other accrued expenses	1,209,250	1,075,591
Accrued Liabilities Current	$ 2,391,313	$ 2,400,090

Long-term Debt (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Debt Instrument [Line Items]
Loan Payable	$ 21,698,568	$ 21,421,420
Less: Current portion	(46,320)	(45,135)
Debt discount	(6,310,002)	(6,893,183)
Long-term debt	15,342,246	14,483,102
Ros Acquisition Offshore [Member]
Debt Instrument [Line Items]
Loan Payable	20,000,000	20,000,000
Amendment To Credit Agreement Adjustment Fee Payable	300,000	0
Midcap and Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Loan Payable	$ 1,398,568	$ 1,421,420

Long-term Debt (Details 1) (USD $)	Jun. 30, 2013
Schedule of maturities due on debt [Line Items]
Remainder of 2013	$ 22,813
2014	47,727
2015	50,670
2016	1,720,463
2017	6,723,781
Thereafter	13,133,114
Total	$ 21,698,568

Long-term Debt (Details 2) (USD $)	Jun. 30, 2013
Estimated future royalty payments [Line Items]
Remainder of 2013	$ 394,000
2014	853,000
2015	1,050,000
2016	1,289,000
2017	1,384,000
Thereafter	8,477,000
Total	$ 13,447,000

Long-term Debt (Details Textual) (USD $)	1 Months Ended	6 Months Ended			6 Months Ended	0 Months Ended	1 Months Ended	6 Months Ended
Long-term Debt (Details Textual) (USD $)	Apr. 23, 2012	Jun. 30, 2013	Jun. 30, 2013 Midcap and Silicon Valley Bank [Member]	Apr. 23, 2012 Midcap and Silicon Valley Bank [Member]	Jun. 30, 2013 Valley Bank Of Belgrade [Member]	Aug. 12, 2013 Ros Acquisition Offshore [Member]	Aug. 24, 2012 Ros Acquisition Offshore [Member]	Jun. 30, 2013 Ros Acquisition Offshore [Member]
Debt Instrument [Line Items]
Debt Instrument Borrowing Capacity Amount							$ 20,000,000
Debt Instrument, Unused Borrowing Capacity, Amount				5,000,000			5,000,000
Debt Instrument Additional Borrowing Limit				3,000,000
Debt Instrument, Interest Rate, Effective Percentage					6.00%
Debt Instrument, Periodic Payment					10,746
Debt Instrument, Maturity Date					Dec. 24, 2030
Line of Credit Facility, Description	The facility allowed borrowings based upon a predetermined formula of up to 80% of Bacterin's eligible accounts receivable, as defined in the credit and security agreement. The Company also amended its existing Loan and Security Agreement with MidCap to allow the Company to borrow up to an additional $3 million for the next nine months in connection with a permitted acquisition. The credit facility carried an interest rate of LIBOR plus 4%, subject to a LIBOR floor rate of 2.5%. The Company also agreed to pay a 0.5% collateral management fee on the average outstanding balance of the facility and 1% of the average unused portion of the facility, as well as a 1% origination fee.						LIBOR plus 12.13%, subject to a LIBOR floor rate of 1.0%.
Royalty Payments Description							royalty of 1.75% on the first $45,000,000 of net sales, plus 1.0% of net sales in excess of $45,000,000 for each of the next ten years.	LIBOR plus 12.13% maturing August 2019
Future Royalty Liability		13,800,000
Proceeds from Other Debt			10,000,000
Royalty liability related to financing		7,341,520
Installment Amount							45,000,000
Amendment To Credit Agreement, Minimum Liquidity Requirement Amount		1,500,000
Minimum Liquidity Requirement Amount		750,000
Amendment To Credit Agreement Adjustment Fee Payable		$ 300,000
Compliance Violations Of Covenants Related To Credit Agreement Description		The Company did not achieve the $8.5 million revenue in the second quarter of 2013 for which we received a waiver in exchange for an additional fee as discussed in Note 15, Subsequent Events below. In addition, the Company did not hire a Chief Executive Officer with 90 days of the resignation of the prior Chief Executive Officer for which we received a waiver in exchange for Board observer rights.				the Company received a waiver from ROS for failure to achieve $8.5 million of revenue in the second quarter of 2013. In exchange for the waiver, the Company agreed to pay a fee of $400,000 when the Company pays, prepays or is required to pay any principal amount of the loan.

Stock-Based Compensation (Details) (USD $)	6 Months Ended
Stock-Based Compensation (Details) (USD $)	Jun. 30, 2013	Jun. 30, 2012
Schedule of activity under stock option plans [Line Items]
Outstanding at January 1, Shares	5,266,535	4,828,910
Granted, Shares	1,281,250	820,625
Exercised, Shares	0	(15,000)
Cancelled or expired, Shares	(530,000)	(1,038,750)
Outstanding at June 30, Shares	6,017,785	4,595,785
Exercisable at June 30, Shares	2,659,701	2,028,993
Outstanding at January 1, Weighted Average Exercise Price	$ 2.02	$ 2.14
Granted, Weighted Average Exercise Price	$ 0.70	$ 2.15
Exercised, Weighted Average Exercise Price	$ 0	$ 1.34
Cancelled or expired, Weighted Average Exercise Price	$ 1.79	$ 1.92
Outstanding at June 30, Weighted Average Exercise Price	$ 1.75	$ 2.19
Exercisable at June 30, Weighted Average Exercise Price	$ 1.86	$ 1.71
Outstanding at January 1, Weighted Average Fair Value At Grant Date	$ 1.03	$ 1.01
Granted, Weighted Average Fair Value At Grant Date	$ 0.50	$ 1.05
Exercised, Weighted Average Fair Value At Grant Date	$ 0	$ 0.45
Cancelled or expired, Weighted Average Fair Value At Grant Date	$ 0.87	$ 0.91
Outstanding at June 30, Weighted Average Fair Value At Grant Date	$ 0.94	$ 1.04
Exercisable at June 30, Weighted Average Fair Value At Grant Date	$ 0.86	$ 0.72

Stock-Based Compensation (Details 1)	6 Months Ended
Stock-Based Compensation (Details 1)	Jun. 30, 2013
Restricted stock award activity [Line Items]
Outstanding at Jan. 1, 2013, Shares	733,900
Awarded, Shares	0
Cancelled, Shares	(112,500)
Vested, Shares	(142,000)
Outstanding at June 30, 2013, Shares	479,400

Stock-Based Compensation (Details Textual) (USD $)	6 Months Ended
Stock-Based Compensation (Details Textual) (USD $)	Jun. 30, 2013	Jun. 30, 2012
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	9,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	808,648
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.12%
Granted, Weighted Average Fair Value At Grant Date	$ 0.50	$ 1.05
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options	$ 199,475
Forfeiture Rate	20.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years 10 months 10 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	63.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Employee Stock Option [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	500,141
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	300,666
ShareBased Compensation Arrangements By Share Based Payment Award Options Unvested Options	3,358,084
Granted, Weighted Average Fair Value At Grant Date	$ 0.98
Restricted Stock [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Allocated Share-based Compensation Expense	31,229	304,184
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Minimum Vesting Period	3 years
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Maximum Vesting Period	5 years
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options	$ 131,769

Warrants (Details) (USD $)	6 Months Ended
Warrants (Details) (USD $)	Jun. 30, 2013
warrant activity [Line Items]
Outstanding at January 1, 2013, Shares	7,321,667
Issued, Shares	4,352,215
Exercised, Shares	0
Expired, Shares	(533,173)
Outstanding at June 30, 2013, Shares	11,140,709
Outstanding at January 1, 2013, Weighted Average Exercise Price	2.20
Issued, Weighted Average Exercise Price	$ 0.57
Exercised, Weighted Average Exercise Price	$ 0
Expired, Weighted Average Exercise Price	$ 2.00
Outstanding at June 30, 2013, Weighted Average Exercise Price	1.57

Warrants (Details 1) (USD $)	3 Months Ended
Warrants (Details 1) (USD $)	Jun. 30, 2013	Jun. 30, 2012
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Value of underlying common stock (per share)	$ 0.45	$ 1.34
Risk free interest rate	0.72%	0.38%
Expected term	6 years 2 months 16 days	4 years 4 months 6 days
Dividend yield	0.00%	0.00%
Volatility	63.00%	65.00%

Warrants (Details 2)	6 Months Ended
Warrants (Details 2)	Jun. 30, 2013	Jun. 30, 2012
Class of Warrant or Right [Line Items]
Outstanding at January 1, 2013, Shares	7,321,667
Derivative warrants issued	4,352,215
Outstanding at June 30, 2013, Shares	11,140,709
Warrant Derivative Liability [Member]
Class of Warrant or Right [Line Items]
Outstanding at January 1, 2013, Shares	1,649,707	1,506,007
Derivative warrants issued	4,352,215	143,700
Derivative warrants exercised	0	0
Outstanding at June 30, 2013, Shares	6,001,922	1,649,707

Warrants (Details Textual) (USD $)	6 Months Ended			3 Months Ended					1 Months Ended
Warrants (Details Textual) (USD $)	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2010 Bridge Loan [Member]	Dec. 31, 2012 Broker [Member]	Dec. 31, 2010 Debt Financing [Member]	Jun. 30, 2013 Lincoln Park Capital Fund Llc [Member]	Jun. 30, 2012 Lincoln Park Capital Fund Llc [Member]	Jun. 30, 2013 Equity Financing [Member]	Jul. 23, 2012 Private Placement [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	1.57	2.20		2.30					1.03
Class of Warrant or Right, Outstanding	11,140,709	7,321,667	1,570,565		375,000	97,828	143,700	4,254,387
Unrealized Gain On Warranty Derivative Liability	$ 1,095,625
Issuance of warrants				297,991					300,895
Class Of Warrant Or Right Issued During Period Value	$ 1,485,313								$ 342,485

Commitments and Contingencies (Details) (USD $)	Jun. 30, 2013
Schedule of future minimum payments by operating lease [Line Items]
Remainder of 2013	$ 122,414
2014	270,993
2015	263,136
2016	263,136
2017	263,136
Thereafter	852,769
Total	$ 2,035,584

Commitments and Contingencies (Details Textual) (USD $)	0 Months Ended	6 Months Ended
Commitments and Contingencies (Details Textual) (USD $)	Apr. 04, 2012	Jun. 30, 2013	Jun. 30, 2012
Schedule of commitment and contingencies [Line Items]
Operating Leases, Rent Expense, Net		$ 128,000	$ 143,000
Contingency Damages Claims	$ 1,648,993.58

Supplemental Disclosure of Cash Flow Information (Details) (USD $)	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Supplemental disclosure of cash flow information
Interest	$ 2,238,636	$ 483,336
Income taxes	0	0
Non-cash activities:
Net shares issued for non-cash consulting expense	143,011	0
Capital lease acquisition	0	177,507
SeaArk Capital, LLC [Member]
Non-cash activities:
Settlement of SeaArk accounts receivable	1,829,647	0
Inventory received in SeaArk settlement	409,838	0
Write-off of SeaArk allowance for doubtful accounts	1,419,809	0
Ros Acquisition Offshore [Member]
Non-cash activities:
ROS adjustment fee	$ 300,000	$ 0

Related Party Transactions (Details Textual) (USD $)			6 Months Ended					1 Months Ended
Related Party Transactions (Details Textual) (USD $)	Jun. 30, 2013	Dec. 31, 2012	Jun. 30, 2013 American Donor Services [Member]	Jun. 30, 2012 American Donor Services [Member]	Jun. 30, 2013 Mr Godfrey [Member]	Jun. 30, 2013 West Coast Tissue Services [Member]	Jun. 30, 2012 West Coast Tissue Services [Member]	Jun. 27, 2012 Mr Cook [Member]
Related Party Transaction [Line Items]
Accounts payable - related party	$ 478,762	$ 418,922
Recovery of Direct Costs			909,120	569,911		337,900	200,700
Servicing Fees, Net					$ 5,000
Number Of Stock Collatoralized For Loan								1,850,000

Subsequent Events (Details Textual)	6 Months Ended	0 Months Ended
Subsequent Events (Details Textual)	Jun. 30, 2013	Aug. 12, 2013 Ros Acquisition Offshore [Member]
Subsequent Event [Line Items]
Compliance Violations Of Covenants Related To Credit Agreement Description	The Company did not achieve the $8.5 million revenue in the second quarter of 2013 for which we received a waiver in exchange for an additional fee as discussed in Note 15, Subsequent Events below. In addition, the Company did not hire a Chief Executive Officer with 90 days of the resignation of the prior Chief Executive Officer for which we received a waiver in exchange for Board observer rights.	the Company received a waiver from ROS for failure to achieve $8.5 million of revenue in the second quarter of 2013. In exchange for the waiver, the Company agreed to pay a fee of $400,000 when the Company pays, prepays or is required to pay any principal amount of the loan.